Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-08-25 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, a foreign issuer. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The content is a press release announcing the approval of Tagrisso in Japan for early lung cancer, including clinical trial results and company information. There are no financial statements or detailed financial performance data. The document is an announcement of a regulatory approval and related information, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement and material information filing by a foreign issuer.
2022-08-25 English
LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of Lynparza in Japan for early breast cancer, including clinical trial results, drug information, and company background. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about the company's product approval and related clinical data. The length is substantial (15,000 characters), and it is not merely an announcement of a report publication. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-25 English
Ultomiris approved in Japan for gMG
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number' and is dated August 25, 2022. It announces a specific corporate event: the approval of the drug Ultomiris in Japan for generalized myasthenia gravis. The text concludes with standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS) or, more specifically, a general announcement that doesn't fit the defined categories like ER, DIV, or MANG. Since it is a broad announcement of a regulatory/market-moving event and not a detailed financial report (10-K, IR) or a presentation (IP), RNS is the most appropriate classification.
2022-08-25 English
Tagrisso approved in Japan for early lung cancer
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number' and is dated August 25, 2022. It announces a specific regulatory/medical event: 'Tagrisso approved in Japan for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer'. The content is a press release detailing a drug approval based on clinical trial data (ADAURA Phase III trial). The presence of the RNS header, the nature of the announcement (product news/regulatory milestone), and the overall structure strongly indicate this is a general regulatory announcement disseminated via the London Stock Exchange's RNS system. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2022-08-25 English
Lynparza approved in Japan for early breast cancer
Regulatory Filings Classification · 100% confidence The document is a press release format, indicated by the 'RNS Number' (Regulatory News Service) header and the date/time stamp. The content announces a specific regulatory event: the approval of the drug Lynparza by the Japanese Ministry of Health, Labour, and Welfare for a specific indication. This type of announcement, which communicates a significant corporate or regulatory event outside of routine financial reporting (like 10-K or ER), fits best under the general 'Regulatory Filings' category (RNS) or potentially a specific announcement type if one were more fitting. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal announcement distributed via RNS, RNS is the most appropriate general classification for this type of market-sensitive news release that doesn't fit the other specific categories like DIRS, DIV, or CAP. It is not a Report Publication Announcement (RPA) because it is the news itself, not an announcement *about* a report being published.
2022-08-25 English
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA granting priority review for Lynparza for a specific indication, including clinical trial data, drug development collaboration, and background on the disease and drug mechanism. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a drug development milestone and regulatory status update. The document length is substantial (15,000 characters) and contains substantive content rather than just an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-16 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.